<![CDATA[EMA’s Review of Daraxonrasib in PDAC Accelerated Under Phased Review Process]]>

RegulatorydaraxonrasibPositive

AI Analysis

Summary

The EMA has initiated a phased review of daraxonrasib for pancreatic cancer while the FDA processes a rolling new drug application submission for the same drug.

Outcome Details

EMA began phased review; FDA rolling NDA submission underway

Importance:6/10

Sentiment:

0.60

EMAregulatory reviewpancreatic canceraccelerated reviewrolling submission

Read the original article

Published by Cancer Network on July 8, 2026 6:32 PM

Read Original